articleThe LancetJul 1, 2010Closed access

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial

ATAndrew TuttMEMark E. RobsonJEJudy E. GarberSMSusan M. DomchekMWM. William Audeh

Breast Cancer Now · King's College London · +18 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

No abstract available for this paper.

Citation impact

1,636
total citations
FWCI
72.15
Percentile
100%
References
45
Citations per year

Authors

15

Topics & keywords

Topics
Keywords
  • Olaparib
  • Medicine
  • Tolerability
  • Breast cancer
  • Cohort
  • PARP inhibitor
  • Internal medicine
  • BRCA mutation
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.

Funding